Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

GSK to Launch New Sustainable Chemistry Center in Brazil

October 28, 2013 10:18 am | News | Comments

GSK announced it has formed a new collaboration with the São Paulo Research Foundation (FAPESP) to create a new Centre of Excellence for Sustainable Chemistry in Brazil.                       


EMA Gives New Regulations on IV Nicardipine

October 28, 2013 10:08 am | News | Comments

The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) has completed a benefit-risk review of intravenous (given into a vein) nicardipine medicines, concluding hat these medicines should only be used to treat acute (sudden) life-threatening high blood pressure and to control high blood pressure after an operation.


Eleven New Genetic Alzheimer's Drug Targets Found

October 28, 2013 9:48 am | News | Comments

The largest international Alzheimer's disease genetics collaboration to date has found 11 new genetic areas of interest that contribute to late onset Alzheimer's Disease (LOAD), doubling the number of potential genetics-based therapeutic targets to interrogate.


Cocaine Dependency Drug Shows Promise

October 25, 2013 2:33 pm | News | Comments

New research published in Journal of the American Medical Association Psychiatry reveals that topiramate, a drug approved by the U.S. Food and Drug Administration (FDA) to treat epilepsy and migraine headaches, also could be the first reliable medication to help treat cocaine dependence. So what were the results of the study? Find out...


Collaboration Brings Genomic Testing to Cancer Drug Developers

October 25, 2013 2:20 pm | News | Comments

Personal Genome Diagnostics Inc. will collaborate with MolecularMD to market a suite of comprehensive personalized medicine services to oncology researchers and drug developers, adding PGDx’s expertise in next-generation sequencing (NGS)-based cancer biomarker discovery to MolecularMD’s capabilities in the development, validation and global delivery of cancer companion diagnostics. Read more...


Rigel Gives Up on Chronic Skin Condition Drug

October 25, 2013 2:04 pm | News | Comments

R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a recently completed Phase 2 clinical study. So how is the development for the other drug in their pipeline going? Find out...


Antibody Frag Improves Alzheimer's in Mice

October 25, 2013 1:07 pm | News | Comments

Researchers have conducted trials with mice by injecting a specific antibody fragment against soluble aggregates of the A peptide, responsible for the toxicity and cell death characteristic of Alzheimer's disease. How quickly were the beneficial effects seen? Find out...


Janssen Joins Structural Genomics Consortium

October 25, 2013 12:24 pm | News | Comments

Janssen Pharmaceuticals NV has joined the Structural Genomics Consortium's (SGC) group to partner in the investigation of epigenetics-based drug research, a new and burgeoning field in the development of future medicines. What is the goal of this partnership? Find out...


Two-Drug Combo Slows Brain Tumors in Mice

October 25, 2013 12:04 pm | News | Comments

A novel combination of two oral targeted drugs dramatically slowed the growth of glioblastoma brain tumors in mice and significantly extended the animals’ survival, report scientists. Why was this approach successful when previous attempts to treat this type of glioblastoma were not? Find out...


Second Alzheimer’s Imaging Drug Approved

October 25, 2013 11:45 am | News | Comments

The U.S. Food and Drug Administration (FDA) today approved Vizamyl (flutemetamol F 18 injection), a radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia. So how does Vizamyl work? Find out...


Trial Evaluates Longer Detox in Prescription Opioid Abusers

October 25, 2013 10:13 am | News | Comments

Patients addicted to prescription opioids who are taking buprenorphine may respond better to tapering of the drug over four weeks than over shorter periods when the taper is followed by naltrexone, according to a clinical trial report.    


Lilly's Tapiero Retiring, Zulueta Promoted

October 25, 2013 9:58 am | News | Comments

Eli Lilly and Co. announced that Alfonso "Chito" Zulueta will be promoted to senior vice president and president of the Emerging Markets business effective Jan. 1, 2014. Zulueta will replace Jacques Tapiero who will retire Jan. 31, 2014.   


FDA Wants Limits on Hydrocodone Painkillers

October 25, 2013 9:51 am | News | Comments

The Food and Drug Administration is recommending new restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.           


Ninety-Six Wells of Flies on a Plate

October 25, 2013 9:39 am | by Andrew S. Wiecek, Editor | Articles | Comments

A growing number of researchers in the Drosophila community are pioneering the use of Drosophila screens to identify potential drug candidates for cancer, cardiovascular disease and neurodegenerative diseases. Is the pharmaceutical industry missing out by not adopting this technique? Find out...


FDA Advisers Unanimously Back J&J Hep C Drug

October 24, 2013 3:36 pm | News | Comments

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government advisers who say the medication should be approved to treat patients infected with the liver-destroying virus.           



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.